Core Viewpoint - Haohai Biological Technology (06826) announced the acquisition of the remaining 20% equity in Shenzhen New Industry Ophthalmic Technology Co., Ltd. for RMB 74 million, aiming to enhance its market position in the ophthalmic high-value consumables sector [1] Group 1: Acquisition Details - The acquisition agreement was signed on November 7, 2025, between Haohai's wholly-owned subsidiary Shanghai Haohai Pharmaceutical Technology and the sellers [1] - After the completion of this acquisition, the company will hold 100% equity in the target company [1] Group 2: Target Company Overview - The target company specializes in the manufacturing and sales of orthokeratology lenses and artificial lenses, as well as the distribution of various imported ophthalmic products in mainland China [1] - The company has been progressively entering the ophthalmic high-value consumables market since acquiring 60% and 20% stakes in 2016 and 2023, respectively [1] Group 3: Strategic Importance - The acquisition is expected to improve the management and operational efficiency of the target company, thereby enhancing the competitiveness of the company's ophthalmic products in the market [1] - The board believes that this acquisition aligns with the company's development needs and overall business strategy [1]

Core Viewpoint - The company, Haohai Biological Technology, is acquiring the remaining 20% equity of Shenzhen New Industry Ophthalmic New Technology Co., Ltd. for RMB 74 million, aiming to enhance its management and operational efficiency in the ophthalmic high-value consumables sector [1] Group 1: Acquisition Details - The acquisition agreement involves Haohai's wholly-owned subsidiary, Shanghai Haohai Pharmaceutical Technology, as the acquirer and includes the transfer of equity from Mr. Zhang, Shenzhen Jiusi, and Shenzhen Baina [1] - Upon completion of the acquisition, the company will hold 100% equity in the target company, which specializes in the manufacturing and sales of orthokeratology lenses and artificial lenses [1] Group 2: Strategic Importance - The target company has been a significant subsidiary since Haohai acquired 60% and 20% stakes in November 2016 and February 2023, respectively [1] - The acquisition aligns with the company's strategic goal to strengthen its position as a leading manufacturer of artificial lenses in China and improve market competitiveness in ophthalmic products [1]

Core Viewpoint - Haohai Biological Technology (06826.HK) announced the acquisition of the remaining 20% equity in Shenzhen New Industry Ophthalmic New Technology Co., Ltd. for RMB 74 million, aiming to enhance its management and operational efficiency in the ophthalmic high-value consumables sector [1] Group 1: Acquisition Details - The acquisition agreement was signed between Shanghai Haohai Pharmaceutical Technology Development Co., Ltd. (a wholly-owned subsidiary of the company) and the sellers (Zhang Jinsong, Shenzhen Jiusi, and Shenzhen Bainai) [1] - Upon completion of the acquisition, the company will hold 100% equity in the target company [1] Group 2: Target Company Overview - The target company is a limited liability company established in China, primarily engaged in the manufacturing and sales of orthokeratology lenses and intraocular lens products [1] - It also distributes various imported ophthalmic products, including intraocular lenses, ophthalmic viscoelastic devices, and sodium hyaluronate gel for glaucoma surgery in mainland China [1] Group 3: Strategic Importance - The company has progressively entered the ophthalmic high-value consumables market since acquiring 60% and 20% stakes in the target company in November 2016 and February 2023, respectively [1] - The target company has become one of the main subsidiaries of the group, contributing to its position as a leading manufacturer of intraocular lens products in China [1] - The board believes that the acquisition aligns with the company's development needs and overall business planning, enhancing market competitiveness in ophthalmic products [1]

Core Viewpoint - The major shareholder of the company, Rao Jie, has completed a share reduction plan, selling a total of 1.5 million shares, which represents 0.1909% of the company's total equity [1] Summary by Relevant Sections Shareholding Changes - After the reduction, Rao Jie holds 22,966,700 shares, accounting for 2.9230% of the total equity [1] - Prior to the reduction, Rao Jie and his concerted parties held a combined 16.9570% of the total equity, which decreased to 16.7661% post-reduction [1] Compliance and Impact - The share reduction was conducted in accordance with regulatory requirements, and it did not result in a change of control over the company [1] - The reduction is stated to have no significant impact on the company's ongoing operations [1]

证券代码：300832 证券简称：新产业 公告编号：2025-086 深圳市新产业生物医学工程股份有限公司 关于持股 5%以上股东的一致行动人兼董事 减持计划实施完成的公告 公司持股 5%以上股东饶微的一致行动人兼董事饶捷保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证本公告内容与信息披露义务人提供的信息一 致。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于 2025 年 9 月 30 日披露了《关于持股 5%以上股东、董事、高级管理人员减持股份的预披 露公告》（公告编号：2025-074，以下简称"减持计划"）。近日，公司收到饶 捷女士出具的《关于股份减持计划实施完成的告知函》，截至 2025 年 11 月 6 日， 其上述预披露的股份减持计划已实施完毕。 根据《上市公司股东减持股份管理暂行办法》《深圳证券交易所创业板股票 上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》《深圳证券交易所上市公司自律监管指引第 18 号——股东及董事、 高级管理人员减持股份》等相关规定，现将上述减持计划的减持结果 ...

Core Insights - Guangdong Province has achieved significant economic growth during the "14th Five-Year Plan" period, with a projected GDP of 14.16 trillion yuan in 2024, maintaining its position as the largest economy in China for 36 consecutive years, with an average annual growth rate of 4.7% over the first four years [1] - The province is focusing on the development of the Guangdong-Hong Kong-Macao Greater Bay Area, leveraging technological innovation to drive industrial upgrades and aiming to establish an international first-class bay area and world-class city cluster [1] Economic Performance - Guangdong's industrial revenue reached 19.41 trillion yuan, and the added value of the service industry was 8.14 trillion yuan, both ranking first in the country [1] - The province's economic reforms are characterized by a focus on high-quality development, with significant breakthroughs in key areas and the replication of successful pilot programs [3] Reform Initiatives - The province has implemented over 60 "national firsts" through the Shenzhen comprehensive reform pilot, with 48 innovative measures promoted nationwide [3] - Guangdong has introduced policies to enhance the business environment, resulting in over 20 batches of application scenario opportunity lists and more than 1,300 innovative projects [3][4] Business Environment - The "Three-Year Action Plan for Building an International First-Class Business Environment in the Greater Bay Area" has been launched, with cities like Guangzhou and Shenzhen accelerating the establishment of innovative business environment pilot cities [4] - As of September, the number of registered business entities in the province exceeded 20 million, with over 9 million being enterprises, indicating a robust development of the private economy [4] Infrastructure and Connectivity - The province is enhancing connectivity within the Greater Bay Area through institutional innovations, facilitating cross-border flows of talent, capital, and data [5] - The "Bay Area Pass" project has been implemented to streamline cross-border travel and cooperation, with significant increases in cross-border vehicle movements and talent exchanges [5] Innovation and Industry Development - Guangdong has maintained its position as the top region for innovation capabilities in China for eight consecutive years, focusing on a comprehensive innovation chain from basic research to technology commercialization [7][8] - The province is promoting both the upgrading of traditional industries and the development of emerging industries, with significant investments in sectors like integrated circuits and new energy storage [9] Collaborative Innovation - The Greater Bay Area is advancing as an international technology innovation center, with collaborative efforts in fields such as artificial intelligence and low-altitude economy [10] - The establishment of joint laboratories and shared access to major technological infrastructures is enhancing regional cooperation and innovation capabilities [10]

Core Viewpoint - The Inner Mongolia Autonomous Region has initiated a "breakthrough" project in technology since 2023, significantly enhancing the enthusiasm for innovation across various sectors, leading to a collaborative environment focused on technological and industrial innovation [2] Group 1: Technological Breakthroughs - A "7+1" breakthrough layout has been established, focusing on key industrial clusters and innovation needs, with 75 key tasks deployed in areas such as energy storage, rare earths, hydrogen energy, and biotechnology, supported by a total financial investment exceeding 670 million yuan, which has attracted an additional 2.8 billion yuan from society [2] - A series of landmark achievements have been made, including the production of 10 pilot demonstration lines in the rare earth sector and the development of 21 new products, generating an additional output value of 300 million yuan from energy-saving coating materials applied in 10 enterprises [3] - The dairy sector has pioneered a β-casein preparation technology with over 80% purity, improving yield by 20% compared to international competitors, while advancements in energy storage and hydrogen energy have strengthened the region's energy base transformation [3] Group 2: Talent Development - The project has attracted high-level talent, with participation from 24 academicians and over 4,000 researchers from 261 universities, research institutes, and enterprises, fostering a collaborative environment for talent development [3] - Significant awards have been achieved, with 15.2% of first prizes and 20% of youth innovation awards in the Inner Mongolia Science and Technology Awards going to teams involved in the "breakthrough" project, covering all major award categories [3] Group 3: Future Plans - The Inner Mongolia Science and Technology Department will ensure the integration of the "breakthrough" project with the "14th Five-Year" technology innovation plan, mobilizing various departments and innovation entities to enhance overall technological innovation efficiency [4]

Core Insights - The China Securities Index Co., Ltd. will officially launch the China Securities Innovation Drug Index and the China Securities Medical Device Index on November 7, providing richer investment targets for the market [1] Group 1: Innovation Drug Index - The China Securities Innovation Drug Index selects listed companies involved in innovative drug research and development, as well as those providing drug research, development, and production services from the Sci-Tech Innovation Board and the Growth Enterprise Market [4] - A total of 50 constituent stocks have been included in the index, such as BeiGene, Boli Tianheng, Kanglong Chemical, and Zhifei Biological [4] - The innovative drug sector has attracted significant investor attention this year, with China's innovative drug pipeline and clinical trial projects ranking among the top globally [4] Group 2: Medical Device Index - The China Securities Medical Device Index selects listed companies that provide medical devices, consumables, and in vitro diagnostic products and services from the Sci-Tech Innovation Board and the Growth Enterprise Market [4] - 50 constituent stocks have been included in this index, including Mindray Medical, United Imaging, New Industry, and Aimeike [4] - The domestic medical device industry is experiencing rapid development, with a positive outlook on innovation-driven import substitution and global expansion [5]

Core Insights - The article highlights the successful IPO of Seres, a luxury electric vehicle company based in Chongqing, which has become the first luxury EV company in China to be listed in both A-share and H-share markets, achieving a market capitalization exceeding HKD 220 billion at opening [1] - Seres raised a net amount of HKD 14.016 billion, marking the largest IPO for a Chinese car company to date and the largest global car IPO in Hong Kong since 2025 [1] - The rise of Seres is attributed to its partnership with Huawei and support from Chongqing state-owned assets, showcasing a successful model of urban industrial investment [1] Group 1: Seres' Rise - Seres transitioned from a traditional car manufacturer, previously known as Xiaokang Co., which focused on micro-vans, to a prominent player in the electric vehicle market after partnering with Huawei in 2021 [2][3] - The collaboration with Huawei allowed Seres to leverage smart automotive solutions, leading to the launch of the Aito series, which significantly boosted its market value [3] - In 2024, Seres achieved sales of 497,000 units, revenue of CNY 145.176 billion, and a net profit of CNY 5.946 billion, becoming the fourth global EV company to achieve profitability for the year [3] Group 2: Support from Chongqing State-Owned Assets - Chongqing's state-owned investment platform, Yufu Holdings, played a crucial role in Seres' growth by establishing a CNY 200 billion industrial investment fund and investing over CNY 3.3 billion to develop a "super factory" for Seres [4][5] - The "super factory" became the core production base for the Aito M9 model, which is expected to deliver 150,000 units in 2024, significantly contributing to Seres' revenue growth [4] - Yufu Holdings continued to support Seres by becoming a major shareholder after Seres acquired the factory for CNY 8.164 billion, creating a positive cycle of state capital investment [4][5] Group 3: Impact on Chongqing's Economy - The development of the electric vehicle industry has led to the establishment of a comprehensive supply chain in Chongqing, with over 100 local parts manufacturers entering Huawei's supply chain [6] - As of October 2025, the Chongqing industrial investment fund has invested approximately CNY 21.4 billion in various projects, including Seres, contributing to the formation of a closed-loop ecosystem in smart connected EVs [6] - The growth of the EV industry has positioned Chongqing as the fourth largest economy in China with a GDP of CNY 3.22 trillion in 2024, and it has become a leader in R&D investment in the central and western regions [7]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [6]. Core Insights - The company achieved a revenue of 3.428 billion yuan in the first three quarters of 2025, showing a year-on-year stability, while the net profit attributable to the parent company was 1.205 billion yuan, reflecting a decline of 12.92% year-on-year [1]. - Domestic main business revenue decreased by 10.95% year-on-year, while overseas main business revenue increased by 21.07% year-on-year, highlighting a shift towards international markets [2]. - The company continues to invest heavily in R&D, with a research and development expense ratio of 10.86%, up 1.27 percentage points year-on-year, contributing to a gradual recovery in gross margin [3]. - The company is advancing high-end installations, with a total of 4,545 units of MAGLUMI X8 sold, and the introduction of MAGLUMI X10 in Q3 2025, indicating a strong position in the high-end chemiluminescence market [4]. Financial Performance Summary - For 2025, the company is projected to achieve revenues of 4.765 billion yuan, with a net profit of 1.801 billion yuan, reflecting a downward adjustment due to industry pressures from centralized procurement and unbundling of testing packages [4]. - The company’s gross margin for the first three quarters of 2025 was 68.73%, down 3.62 percentage points year-on-year, but showed a sequential improvement in Q3 [3]. - The projected earnings per share (EPS) for 2025 is 2.29 yuan, with a price-to-earnings (P/E) ratio of 27.36 [5].